Journal
EXPERT REVIEW OF ANTICANCER THERAPY
Volume 15, Issue 12, Pages 1367-1369Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/14737140.2015.1110488
Keywords
fibroblast growth factor receptor; kidney; personalized medicine; precision medicine; renal cell carcinoma; targeted therapy; vascular endothelial growth factor receptor
Categories
Ask authors/readers for more resources
Fibroblast growth factor receptor (FGFR) pathway is involved in driving vascular endothelial growth factor (VEGF)-independent tumor angiogenesis, as a compensatory mechanism to escape VEGF-targeted therapies. Therefore, targeting FGF/FGFR axis seems to be a promising strategy in order to inhibit tumor angiogenesis and reduce resistance to VEGF receptor-tyrosine kinase inhibitors. This editorial is focused on the role of FGF/FGFR pathway in renal cell carcinoma and on the ongoing trials of emerging agents targeting this axis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available